The current role of SCT in LBCL in the era of novel therapies: identifying patients who may benefit
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-06-19
Просмотров: 35
Описание:
In this video, Daniel Landsburg, MD, University of Pennsylvania, Philadelphia, PA, briefly comments on the evolving role of stem cell transplantion (SCT) in the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients, noting that novel therapies such as CAR T-cells and bispecific antibodies are increasingly replacing SCT as a treatment option. However, he suggests that SCT may still be beneficial for a small proportion of patients with favorable molecular risk features or those who relapse late after initial therapy, offering a potentially higher cure rate and prolonged progression-free survival (PFS). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
